Third Rock Launches Ember Therapeutics With Focus On Obesity And Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
The sole investor in a $34 million Series A financing, Third Rock hopes Ember can be a pioneer in development of obesity drugs that augment brown fat levels.